Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.

Hasegawa H, Bissonnette RP, Gillings M, Sasaki D, Taniguchi H, Kitanosono H, Tsuruda K, Kosai K, Uno N, Morinaga Y, Imaizumi Y, Miyazaki Y, Yanagihara K.

Cancer Sci. 2016 Aug;107(8):1124-33. doi: 10.1111/cas.12971. Epub 2016 Jun 22.

2.

The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.

Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH.

Cancer Prev Res (Phila). 2012 Oct;5(10):1195-202. doi: 10.1158/1940-6207.CAPR-11-0524. Epub 2012 Aug 27.

3.

Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism.

Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MA.

Mol Pharmacol. 2012 Feb;81(2):228-38. doi: 10.1124/mol.111.072967. Epub 2011 Nov 3.

4.

The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.

Li Y, Shen Q, Kim HT, Bissonnette RP, Lamph WW, Yan B, Brown PH.

Breast Cancer Res Treat. 2011 Aug;128(3):667-77. doi: 10.1007/s10549-010-1083-9. Epub 2010 Sep 7.

5.

Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Hill J, Bissonnette RP, Brown PH, Medina D, Aldaz CM.

Cancer Prev Res (Phila). 2009 Feb;2(2):175-84. doi: 10.1158/1940-6207.CAPR-08-0104. Epub 2009 Jan 27.

6.

Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LR.

Cancer Prev Res (Phila). 2008 Aug;1(3):208-14. doi: 10.1158/1940-6207.CAPR-08-0021.

7.

Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH.

J Biol Chem. 2009 Jan 2;284(1):345-53. doi: 10.1074/jbc.M804721200. Epub 2008 Oct 28.

8.

Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models.

Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Zhang Y, Hill J, Bissonnette RP, Medina D, Brown PH, Aldaz CM.

BMC Med Genomics. 2008 Sep 11;1:40. doi: 10.1186/1755-8794-1-40.

9.

G0S2 is an all-trans-retinoic acid target gene.

Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R, Dmitrovsky E.

Int J Oncol. 2008 Aug;33(2):397-404.

10.

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.

Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH.

Br J Cancer. 2008 Apr 22;98(8):1380-8. doi: 10.1038/sj.bjc.6604320. Epub 2008 Mar 25.

11.

In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma.

Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR.

Clin Cancer Res. 2008 Jan 15;14(2):589-96. doi: 10.1158/1078-0432.CCR-07-0269. Erratum in: Clin Cancer Res. 2009 Jan 1;15(1):416.

12.

The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.

Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH.

Clin Cancer Res. 2007 Oct 15;13(20):6224-31.

13.

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Hudson AR, Roach SL, Higuchi RI, Phillips DP, Bissonnette RP, Lamph WW, Yen J, Li Y, Adams ME, Valdez LJ, Vassar A, Cuervo C, Kallel EA, Gharbaoui CJ, Mais DE, Miner JN, Marschke KB, Rungta D, Negro-Vilar A, Zhi L.

J Med Chem. 2007 Sep 20;50(19):4699-709. Epub 2007 Aug 17.

PMID:
17705362
14.

Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.

Wu K, DuPré E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH.

Breast Cancer Res Treat. 2006 Mar;96(2):147-57. Epub 2005 Nov 5.

PMID:
16273314
15.

Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.

Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW.

Cancer Lett. 2006 Aug 28;240(2):225-33. Epub 2005 Nov 3.

PMID:
16271436
16.

The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP.

Lung Cancer. 2005 Oct;50(1):9-18.

PMID:
15993980
17.

A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.

Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW.

Clin Cancer Res. 2004 Dec 15;10(24):8656-64.

18.

Nuclear receptor activation and interaction with morphine.

Royal W 3rd, Leander M, Chen YE, Major EO, Bissonnette RP.

J Neuroimmunol. 2004 Dec;157(1-2):61-5.

PMID:
15579281
19.

RXR-induced TNF-alpha suppression is reversed by morphine in activated U937 cells.

Mou L, Lankford-Turner P, Leander MV, Bissonnette RP, Donahoe RM, Royal W.

J Neuroimmunol. 2004 Feb;147(1-2):99-105.

PMID:
14741437
20.

Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax.

Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW.

Br J Cancer. 2002 Aug 27;87(5):555-61.

Supplemental Content

Loading ...
Support Center